Procalcitonin guided antibiotic therapy and hospitalization in patients with lower respiratory tract infections: a prospective, multicenter, randomized controlled trial
Authors:
- Philipp SchuetzPSPhilipp Schuetz
- Mirjam Christ-CrainMCMirjam Christ-Crain
- Marcel WolbersMWMarcel Wolbers
- Ursula SchildUSUrsula Schild
- Robert ThomannRTRobert Thomann
- Claudine FalconnierCFClaudine Falconnier
- Isabelle WidmerIWIsabelle Widmer
- Stefanie NeidertSNStefanie Neidert
- Claudine A BlumCBClaudine A Blum
- Ronald SchönenbergerRSRonald Schönenberger
- Christoph HenzenCHChristoph Henzen
- Thomas BregenzerTBThomas Bregenzer
Open Access
- 5 July 2007
- journal article
- research article
- Published by Springer Nature in BMC Health Services Research
- Vol. 7 (1) , 102
Abstract
Background: Lower respiratory tract infections like acute bronchitis, exacerbated chronic obstructive pulmonary disease and community-acquired pneumonia are often unnecessarily treated with antibiotics, mainly because of physicians' difficulties to distinguish viral from bacterial cause and to estimate disease-severity. The goal of this trial is to compare medical outcomes, use of antibiotics and hospital resources in a strategy based on enforced evidence-based guidelines versus procalcitonin guided antibiotic therapy in patients with lower respiratory tract infections. Methods and design: We describe a prospective randomized controlled non-inferiority trial with an open intervention. We aim to randomize over a fixed recruitment period of 18 months a minimal number of 1002 patients from 6 hospitals in Switzerland. Patients must be >18 years of age with a lower respiratory tract infections <28 days of duration. Patients with no informed consent, not fluent in German, a previous hospital stay within 14 days, severe immunosuppression or chronic infection, intravenous drug use or a terminal condition are excluded. Randomization to either guidelines-enforced management or procalcitonin-guided antibiotic therapy is stratified by centre and type of lower respiratory tract infections. During hospitalization, all patients are reassessed at days 3, 5, 7 and at the day of discharge. After 30 and 180 days, structured phone interviews by blinded medical students are conducted. Depending on the randomization allocation, initiation and discontinuation of antibiotics is encouraged or discouraged based on evidence-based guidelines or procalcitonin cut off ranges, respectively. The primary endpoint is the risk of combined disease-specific failure after 30 days. Secondary outcomes are antibiotic exposure, side effects from antibiotics, rate and duration of hospitalization, time to clinical stability, disease activity scores and cost effectiveness. The study hypothesis is that procalcitonin-guidance is non-inferior (i.e., at worst a 7.5% higher combined failure rate) to the management with enforced guidelines, but is associated with a reduced total antibiotic use and length of hospital stay. Discussion: Use of and prolonged exposure to antibiotics in lower respiratory tract infections is high. The proposed trial investigates whether procalcitonin-guidance may safely reduce antibiotic consumption along with reductions in hospitalization costs and antibiotic resistance. It will additionally generate insights for improved prognostic assessment of patients with lower respiratory tract infections. Trial registration: ISRCTN95122877Keywords
This publication has 35 references indexed in Scilit:
- Copeptin, C-Reactive Protein, and Procalcitonin as Prognostic Biomarkers in Acute Exacerbation of COPDChest, 2007
- Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumoniaBMC Infectious Diseases, 2007
- Circulating levels of copeptin, a novel biomarker, in lower respiratory tract infectionsEuropean Journal of Clinical Investigation, 2007
- Antibiotic Treatment of Exacerbations of COPDChest, 2007
- Circulating levels of pro‐atrial natriuretic peptide in lower respiratory tract infectionsJournal of Internal Medicine, 2006
- Procalcitonin Guidance of Antibiotic Therapy in Community-acquired PneumoniaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Pro-adrenomedullin to predict severity and outcome in community-acquired pneumonia [ISRCTN04176397]Critical Care, 2006
- Assay for the Measurement of Copeptin, a Stable Peptide Derived from the Precursor of VasopressinClinical Chemistry, 2006
- Guidelines for the management of adult lower respiratory tract infectionsEuropean Respiratory Journal, 2005
- Assessing the Quality of Clinical Data in a Computer-based Record for Calculating the Pneumonia Severity IndexJournal of the American Medical Informatics Association, 2000